Johnson & Johnson: 138 Years of Pioneering Healthcare

Science and Technology Will Advance Human Health More in the Next Decade Than It Has in the Last Century, Says Joaquin Duato, Johnson & Johnson CEO

Johnson & Johnson was founded in 1886 and is now one of the largest healthcare companies in the world, consistently ranking among the top biotech and pharmaceutical companies based on market capitalisation.

Headquartered in New Jersey, US, but with its over 130,000 employees spanning the world, the company comprises two main businesses: J&J Innovative Medicine, and J&J MedTech, as well as subsidiaries including Band-Aid, Neutrogena, and Tylenol. 

Rooted in a belief that health is everything, Johnson & Johnson has developed strength in healthcare innovation to work towards its goal of building a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal.

The past of healthcare looking to the future

Johnson & Johnson is looking toward a future of transformational science, innovative technology and geographic expansion funded by a maintained multi-faceted and disciplined capital allocation strategy. Coming into 2024, the company is looking towards operational sales growth in the range of 5-6%.

“Science and technology will advance human health more in the next decade than it has in the last century, leading to more effective and personalised treatment, earlier intervention, and smarter, less invasive healthcare,” believes Joaquin Duato, Chairman and Chief Executive Officer. 

“The breadth of our scientific capabilities, diverse portfolio and robust pipelines uniquely positions Johnson & Johnson to be a leader in this next wave of innovation while delivering strong financial performance.”

Duato has been with Johnson & Johnson for over three decades, serving as Vice Chairman of the Executive Committee before becoming Jonhson & Johnson’s eighth CEO in January 2022 and Chairman in January 2023. Duato is Johnson & Johnson’s first CEO with dual citizenship, which he holds between the US and Spain. He has an MBA from ESADE in Barcelona, Spain, and a Master of International Management from Thunderbird School of Global Management in Phoenix, Arizona. Previously, he has served on the board of UNIXEF USA, as the Chairman of PhRMA and as an Advisory Board Member of Tsinghua University School of Pharmaceutical Sciences.

In his vision for Jonhson & Johnson, he isn’t just looking to the next technological developments — he is developing a vision for the company’s long term growth and success. 

“We’ve created a clear set of steps to reinvent the business guided by our North Star — saving and improving patient lives,” he says. 

“Today, when it comes to the vision for Johnson & Johnson, I’m once again looking 25 years out, steering toward a horizon where we have achieved transformational medical innovations.”

**************

Make sure you check out the latest industry news and insights at Healthcare Digital and also sign up to our global conference series - Tech & AI LIVE 2024

**************

Healthcare Digital is a BizClik brand 

*************

Share

Feature Articles

AstraZeneca Company Profile, as CEO Soriot Lands pay Deal

As it's announced AstraZeneca's CEO Pascal Soriot's package could rise by as much as US$24mn we explore the history of the UK's most valuable business

US Academic Medical Centres 'Struggling' says McKinsey

McKinsey report reveals cost inflation is forcing AMCs to find operational efficiencies, or face cutting back on crucial training & education programmes

J&J Community Initiatives Tackle US Healthcare Chasm

Johnson & Johnson to support community-led US health groups that support marginalised communities in bid to level-up healthcare provision across the US

PitchBook: Healthcare Private Equity Deals see Decline

McKinsey: ‘Women’s Healthcare Neglected for Decades'

EY Blood Donation Blockchain Pilot 'Healthcare Breakthrough'